JP2020512272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512272A5 JP2020512272A5 JP2019522244A JP2019522244A JP2020512272A5 JP 2020512272 A5 JP2020512272 A5 JP 2020512272A5 JP 2019522244 A JP2019522244 A JP 2019522244A JP 2019522244 A JP2019522244 A JP 2019522244A JP 2020512272 A5 JP2020512272 A5 JP 2020512272A5
- Authority
- JP
- Japan
- Prior art keywords
- octadeca
- diene
- dimethylamino
- bis
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cationic lipid Chemical class 0.000 claims 60
- 239000000203 mixture Substances 0.000 claims 14
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- JMOLZNNXZPAGBH-UHFFFAOYSA-N hexyldecanoic acid Chemical compound CCCCCCCCC(C(O)=O)CCCCCC JMOLZNNXZPAGBH-UHFFFAOYSA-N 0.000 claims 7
- 229950004531 hexyldecanoic acid Drugs 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000003287 optical effect Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- FCCCRBDJBTVFSJ-UHFFFAOYSA-N butanehydrazide Chemical compound CCCC(=O)NN FCCCRBDJBTVFSJ-UHFFFAOYSA-N 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- ZBPYTVBKHKUNHG-VOTSOKGWSA-N (e)-non-3-enoic acid Chemical compound CCCCC\C=C\CC(O)=O ZBPYTVBKHKUNHG-VOTSOKGWSA-N 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- PITBYSVUWVIAFD-KFOZCGKISA-N (2S)-2-amino-3-(1H-imidazol-5-yl)-N',N'-bis[(9Z,12Z)-octadeca-9,12-dienyl]propanehydrazide Chemical compound N[C@H](C(=O)NN(CCCCCCCC\C=C/C\C=C/CCCCC)CCCCCCCC\C=C/C\C=C/CCCCC)CC=1N=CNC=1 PITBYSVUWVIAFD-KFOZCGKISA-N 0.000 claims 1
- CMZVMMOUEVEBNB-DNSMMJTHSA-N (2S)-2-amino-6-(dimethylamino)-N',N'-bis[(9Z,12Z)-octadeca-9,12-dienyl]hexanehydrazide Chemical compound N[C@H](C(=O)NN(CCCCCCCC\C=C/C\C=C/CCCCC)CCCCCCCC\C=C/C\C=C/CCCCC)CCCCN(C)C CMZVMMOUEVEBNB-DNSMMJTHSA-N 0.000 claims 1
- VHJBVQFNRNYMQB-KWXKLSQISA-N (6Z,9Z,28Z,31Z)-N-[4-(dimethylamino)butoxy]heptatriaconta-6,9,28,31-tetraen-19-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(CCCCCCCC\C=C/C\C=C/CCCCC)NOCCCCN(C)C VHJBVQFNRNYMQB-KWXKLSQISA-N 0.000 claims 1
- PCLHLDAOQIGKRY-KWXKLSQISA-N (9Z,12Z)-N-[2-[4-(dimethylamino)butoxy]ethyl]-N-[(9Z,12Z)-octadeca-9,12-dienyl]octadeca-9,12-dien-1-amine Chemical compound CN(CCCCOCCN(CCCCCCCC\C=C/C\C=C/CCCCC)CCCCCCCC\C=C/C\C=C/CCCCC)C PCLHLDAOQIGKRY-KWXKLSQISA-N 0.000 claims 1
- KEJCBBGPFXFEGL-KWXKLSQISA-N (9Z,12Z)-N-[4-(dimethylamino)butoxy]-N-[(9Z,12Z)-octadeca-9,12-dienyl]octadeca-9,12-dien-1-amine Chemical compound C(CCCCCCC\C=C/C\C=C/CCCCC)N(OCCCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC KEJCBBGPFXFEGL-KWXKLSQISA-N 0.000 claims 1
- LGUHRXVWLKOOIM-MAZCIEHSSA-N 1,1-bis[(9Z,12Z)-octadeca-9,12-dienyl]-2-(4-pyrrolidin-1-ylbutyl)hydrazine Chemical compound C(CCCCCCC\C=C/C\C=C/CCCCC)N(NCCCCN1CCCC1)CCCCCCCC\C=C/C\C=C/CCCCC LGUHRXVWLKOOIM-MAZCIEHSSA-N 0.000 claims 1
- YXRNXZUIQNFQAF-MAZCIEHSSA-N 1,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]-1-(4-pyrrolidin-1-ylbutyl)hydrazine Chemical compound C(CCCCCCC\C=C/C\C=C/CCCCC)N(NCCCCCCCC\C=C/C\C=C/CCCCC)CCCCN1CCCC1 YXRNXZUIQNFQAF-MAZCIEHSSA-N 0.000 claims 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 claims 1
- KMZBQHTXZUTRNF-XUGPUNSISA-N 2-[(4S)-4-amino-5-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]hydrazinyl]-5-oxopentyl]guanidine Chemical compound N[C@@H](CCCNC(=N)N)C(=O)NN(CCCCCCCC\C=C/C\C=C/CCCCC)CCCCCCCC\C=C/C\C=C/CCCCC KMZBQHTXZUTRNF-XUGPUNSISA-N 0.000 claims 1
- XUJZMVGVGXYVEI-KWXKLSQISA-N 2-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]hydrazinyl]-N,N-dimethylethanamine Chemical compound C(CCCCCCC\C=C/C\C=C/CCCCC)N(NCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC XUJZMVGVGXYVEI-KWXKLSQISA-N 0.000 claims 1
- SMMHSCDDEPIVKA-MAZCIEHSSA-N 2-[2-(1H-imidazol-5-yl)ethyl]-1,1-bis[(9Z,12Z)-octadeca-9,12-dienyl]hydrazine Chemical compound C(CCCCCCC\C=C/C\C=C/CCCCC)N(NCCC=1N=CNC=1)CCCCCCCC\C=C/C\C=C/CCCCC SMMHSCDDEPIVKA-MAZCIEHSSA-N 0.000 claims 1
- VBDLQRZMCWWELB-MAZCIEHSSA-N 2-[2-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]hydrazinyl]ethyl]guanidine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCN(CCCCCCCC\C=C/C\C=C/CCCCC)NCCNC(N)=N VBDLQRZMCWWELB-MAZCIEHSSA-N 0.000 claims 1
- VHFVFEIQUCUIOM-MAZCIEHSSA-N 2-[bis[(9z,12z)-octadeca-9,12-dienyl]amino]ethanol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCN(CCO)CCCCCCCC\C=C/C\C=C/CCCCC VHFVFEIQUCUIOM-MAZCIEHSSA-N 0.000 claims 1
- HDCINGCPASQISP-KWXKLSQISA-N 4-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]hydrazinyl]-N,N-dimethylbutan-1-amine Chemical compound C(CCCCCCC\C=C/C\C=C/CCCCC)N(NCCCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC HDCINGCPASQISP-KWXKLSQISA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- OKBLSUJHPKWGQE-UHFFFAOYSA-N CN(CCN(NCCCCCCCCCC(=O)O)CCCCCCCCCC(=O)O)C Chemical compound CN(CCN(NCCCCCCCCCC(=O)O)CCCCCCCCCC(=O)O)C OKBLSUJHPKWGQE-UHFFFAOYSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- CRXZKQSXIBSCFF-KWXKLSQISA-N N,N-dimethyl-2-[[(9Z,12Z)-octadeca-9,12-dienyl]-[[(9Z,12Z)-octadeca-9,12-dienyl]amino]amino]ethanamine Chemical compound C(CCCCCCC\C=C/C\C=C/CCCCC)N(NCCCCCCCC\C=C/C\C=C/CCCCC)CCN(C)C CRXZKQSXIBSCFF-KWXKLSQISA-N 0.000 claims 1
- UAADMOJRWLQUQA-KWXKLSQISA-N N,N-dimethyl-4-[[(9Z,12Z)-octadeca-9,12-dienyl]-[[(9Z,12Z)-octadeca-9,12-dienyl]amino]amino]butan-1-amine Chemical compound C(CCCCCCC\C=C/C\C=C/CCCCC)N(NCCCCCCCC\C=C/C\C=C/CCCCC)CCCCN(C)C UAADMOJRWLQUQA-KWXKLSQISA-N 0.000 claims 1
- ICPXYZBYAQSPIR-KWXKLSQISA-N N,N-dimethyl-N'-[(9Z,12Z)-octadeca-9,12-dienoxy]-N'-[(9Z,12Z)-octadeca-9,12-dienyl]butane-1,4-diamine Chemical compound CN(CCCCN(OCCCCCCCC\C=C/C\C=C/CCCCC)CCCCCCCC\C=C/C\C=C/CCCCC)C ICPXYZBYAQSPIR-KWXKLSQISA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- NYLILAFLPNVBFR-MAZCIEHSSA-N [bis[(9Z,12Z)-octadeca-9,12-dienyl]amino] 2-(1H-imidazol-5-yl)acetate Chemical compound N1C=NC(=C1)CC(=O)ON(CCCCCCCC\C=C/C\C=C/CCCCC)CCCCCCCC\C=C/C\C=C/CCCCC NYLILAFLPNVBFR-MAZCIEHSSA-N 0.000 claims 1
- MDILOUXGHNWGBK-MAZCIEHSSA-N [bis[(9Z,12Z)-octadeca-9,12-dienyl]amino] 2-(diaminomethylideneamino)acetate Chemical compound C(CCCCCCC\C=C/C\C=C/CCCCC)N(OC(CNC(=N)N)=O)CCCCCCCC\C=C/C\C=C/CCCCC MDILOUXGHNWGBK-MAZCIEHSSA-N 0.000 claims 1
- DNSVCGRKYJTVEB-KWXKLSQISA-N [bis[(9Z,12Z)-octadeca-9,12-dienyl]amino] 2-(dimethylamino)acetate Chemical compound C(CCCCCCC\C=C/C\C=C/CCCCC)N(OC(CN(C)C)=O)CCCCCCCC\C=C/C\C=C/CCCCC DNSVCGRKYJTVEB-KWXKLSQISA-N 0.000 claims 1
- ADLXHLDQFCVXEC-QYCRHRGJSA-N [bis[(9Z,12Z)-octadeca-9,12-dienyl]amino] 4-(4-methylpiperazin-1-yl)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCN(CCCCCCCC\C=C/C\C=C/CCCCC)OC(=O)CCCN1CCN(C)CC1 ADLXHLDQFCVXEC-QYCRHRGJSA-N 0.000 claims 1
- GINJSCGTIDOCCQ-KWXKLSQISA-N [bis[(9Z,12Z)-octadeca-9,12-dienyl]amino] 4-(dimethylamino)butanoate Chemical compound C(CCCCCCC\C=C/C\C=C/CCCCC)N(OC(CCCN(C)C)=O)CCCCCCCC\C=C/C\C=C/CCCCC GINJSCGTIDOCCQ-KWXKLSQISA-N 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 claims 1
- 238000012226 gene silencing method Methods 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 150000004671 saturated fatty acids Chemical class 0.000 claims 1
- 150000004670 unsaturated fatty acids Chemical group 0.000 claims 1
- 0 C*(CN(*)*(C)C1OC1*(C)*(C)C(C1)*1N(*)S)** Chemical compound C*(CN(*)*(C)C1OC1*(C)*(C)C(C1)*1N(*)S)** 0.000 description 3
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418844P | 2016-11-08 | 2016-11-08 | |
| US62/418,844 | 2016-11-08 | ||
| US201762507829P | 2017-05-18 | 2017-05-18 | |
| US62/507,829 | 2017-05-18 | ||
| PCT/IL2017/051212 WO2018087753A1 (en) | 2016-11-08 | 2017-11-07 | Cationic lipids for nucleic acid delivery and preparation thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512272A JP2020512272A (ja) | 2020-04-23 |
| JP2020512272A5 true JP2020512272A5 (https=) | 2020-12-03 |
| JP7075669B2 JP7075669B2 (ja) | 2022-05-26 |
Family
ID=62109569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522244A Active JP7075669B2 (ja) | 2016-11-08 | 2017-11-07 | 核酸送達用カチオン性脂質及びその調製物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11851389B2 (https=) |
| EP (1) | EP3538515B1 (https=) |
| JP (1) | JP7075669B2 (https=) |
| CN (1) | CN110167922B (https=) |
| AU (1) | AU2017356699B2 (https=) |
| DK (1) | DK3538515T3 (https=) |
| ES (1) | ES2928358T3 (https=) |
| MX (1) | MX2019005287A (https=) |
| PT (1) | PT3538515T (https=) |
| WO (1) | WO2018087753A1 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| KR102591743B1 (ko) | 2018-06-08 | 2023-10-19 | 후지필름 가부시키가이샤 | 화합물 또는 그 염 및 지질 입자 |
| US12419965B2 (en) | 2018-10-01 | 2025-09-23 | BioNTech SE | RNA particles comprising polysarcosine |
| HRP20240586T1 (hr) | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| MX2021005448A (es) * | 2018-11-13 | 2021-08-11 | Oncorus Inc | Polinucleotidos encapsulados y metodos de uso. |
| BR112021010853A2 (pt) * | 2018-12-05 | 2021-08-31 | Intellia Therapeutics, Inc. | Lipídios de amina modificados |
| WO2020246581A1 (ja) * | 2019-06-07 | 2020-12-10 | 富士フイルム株式会社 | 脂質組成物 |
| EP4059505B1 (en) * | 2019-11-15 | 2024-02-21 | FUJIFILM Corporation | Lipid composition |
| CN115335084A (zh) * | 2020-03-25 | 2022-11-11 | 生物技术公司 | 包含聚肌氨酸的rna颗粒 |
| EP4132576A1 (en) | 2020-04-09 | 2023-02-15 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| WO2021204175A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticle composition |
| EP4153560A4 (en) * | 2020-05-19 | 2024-04-24 | Ramot at Tel-Aviv University Ltd. | LIPID PARTICLES FOR NUCLEIC ACID DELIVERY AND CLINICAL APPLICATIONS THEREOF |
| ES3054438T3 (en) * | 2020-07-16 | 2026-02-03 | Acuitas Therapeutics Inc | Cationic lipids for use in lipid nanoparticles |
| IL301536A (en) * | 2020-09-23 | 2023-05-01 | Translate Bio Inc | Cationic lipids based on piperazine |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN113185421B (zh) * | 2020-11-27 | 2022-01-25 | 广州市锐博生物科技有限公司 | 脂质化合物及其组合物 |
| WO2022168085A1 (en) * | 2021-02-02 | 2022-08-11 | Ramot At Tel-Aviv University Ltd. | Lipids suitable for nucleic acid delivery |
| CN115197078B (zh) * | 2021-04-08 | 2024-06-04 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
| CN117510830A (zh) * | 2021-04-08 | 2024-02-06 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
| EP4320093A1 (en) * | 2021-04-09 | 2024-02-14 | Pfizer Inc. | Methods for producing of lipids |
| US20240207442A1 (en) * | 2021-04-22 | 2024-06-27 | The Board Of Regents Of The University Of Texas System | All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo |
| EP4310071A4 (en) * | 2021-05-28 | 2024-11-20 | Beijing Tricisionbio Therapeutics Inc. | LIPID COMPOUND AND USE THEREOF IN THE ADMINISTRATION OF NUCLEIC ACID |
| EP4370134A4 (en) | 2021-07-13 | 2025-08-06 | Technion Res & Dev Foundation | COMPOSITIONS AND METHODS FOR TREATING A HEALTH CONDITION |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN115403761B (zh) * | 2021-07-23 | 2025-04-25 | 天津键凯科技有限公司 | 一种多元甘醇修饰的脂质化合物及其制备方法和应用 |
| CN115010681A (zh) * | 2021-09-07 | 2022-09-06 | 安徽荣灿生物科技有限公司 | 一类阳离子脂质体分子及其制备和应用 |
| CN117440943B (zh) * | 2021-10-15 | 2025-09-30 | 厦门赛诺邦格生物科技股份有限公司 | 含氮的阳离子脂质及其应用 |
| CN113999128B (zh) * | 2021-11-25 | 2024-05-10 | 苏州科锐迈德生物医药科技有限公司 | 脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
| EP4458805A4 (en) * | 2021-12-31 | 2026-01-28 | Xiamen Sinopeg Biotech Co Ltd | CATIONIC LIPID CONTAINING A FUNCTIONAL GROUP ON A SIDE CHAIN, AND ITS USE |
| CN114874150A (zh) * | 2022-02-22 | 2022-08-09 | 中国科学院基础医学与肿瘤研究所(筹) | 一种双价可电离脂质化合物、组合物及其应用 |
| CN114213347B (zh) * | 2022-02-22 | 2022-05-20 | 中国科学院基础医学与肿瘤研究所(筹) | 一种双价可电离脂质化合物、组合物及其应用 |
| WO2023165582A1 (zh) * | 2022-03-04 | 2023-09-07 | 益杰立科(上海)生物科技有限公司 | 靶向递送系统和方法 |
| CN114874146B (zh) * | 2022-03-25 | 2023-09-12 | 圣诺生物医药技术(苏州)有限公司 | 组氨酸脂质、组氨酸脂质纳米颗粒及其制备方法和应用 |
| CN116354836A (zh) * | 2022-03-25 | 2023-06-30 | 深圳市新合生物医疗科技有限公司 | 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统 |
| CN117460711B (zh) * | 2022-06-02 | 2025-07-08 | 厦门赛诺邦格生物科技股份有限公司 | 一种含有不饱和键的氨基酸阳离子脂质 |
| CN116444395A (zh) * | 2022-06-27 | 2023-07-18 | 上海云沂生物医药科技有限公司 | 一种氨基脂质、其合成方法、颗粒及用途 |
| EP4585586A4 (en) * | 2022-09-09 | 2025-12-03 | Xiamen Sinopeg Biotech Co Ltd | CARBON CORE CATIONIC LIPID |
| AU2023413766A1 (en) | 2022-12-23 | 2025-05-29 | Biontech Delivery Technologies Gmbh | Composition |
| WO2024160826A1 (en) | 2023-01-31 | 2024-08-08 | BioNTech SE | Compositions and methods |
| CN116143707B (zh) * | 2023-02-24 | 2024-04-19 | 山东大学 | 一种碱基可电离脂质及其制备方法与应用 |
| CN117384055B (zh) * | 2023-04-27 | 2024-11-19 | 仁景(苏州)生物科技有限公司 | 用于递送治疗剂的可电离脂质及其用途 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN121729406A (zh) * | 2023-06-13 | 2026-03-24 | 特拉维夫大学拉莫特有限公司 | 具有提高的稳定性的可生物降解的氨基甲酸酯脂质 |
| WO2025027019A1 (en) | 2023-07-31 | 2025-02-06 | BioNTech SE | Method of determining nucleic acid concentration in aqueous solution or dispersion |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| WO2025093665A1 (en) | 2023-10-31 | 2025-05-08 | BioNTech SE | Particles, compositions and methods |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| FR3155424A1 (fr) | 2023-11-15 | 2025-05-23 | BioNTech SE | Compositions immunogènes contre le sars-cov-2 |
| WO2025133105A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Compositions and methods |
| WO2025143892A1 (ko) * | 2023-12-29 | 2025-07-03 | 주식회사 삼양홀딩스 | 약물전달용 나노입자의 조성물 |
| WO2025149492A1 (en) | 2024-01-08 | 2025-07-17 | BioNTech SE | Rna encoding an immune inhibitory il-1 family member |
| WO2025160118A1 (en) * | 2024-01-22 | 2025-07-31 | The Trustees Of The University Of Pennsylvania | Compositions and methods for hematopoietic stem cell (hsc) targeted delivery of therapeutic agents |
| WO2025176732A1 (en) | 2024-02-20 | 2025-08-28 | BioNTech SE | Compositions and methods |
| WO2025215636A1 (en) | 2024-04-08 | 2025-10-16 | Yeda Research And Development Co. Ltd. | Anti-defense system polypeptides and uses thereof |
| WO2025228979A1 (en) | 2024-04-30 | 2025-11-06 | Neovac Ltd. | Lipids nanoparticle formulations suitable for lung targeting |
| WO2025245869A1 (zh) * | 2024-05-31 | 2025-12-04 | 清华大学 | 含有精氨酸结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途 |
| WO2025261607A1 (en) | 2024-06-21 | 2025-12-26 | BioNTech SE | Particles, compositions and methods |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026009227A1 (en) | 2024-07-04 | 2026-01-08 | Yeda Research And Development Co. Ltd. | Compositions for downregulating zeb2 in macrophages and uses thereof |
| WO2026013059A1 (en) | 2024-07-08 | 2026-01-15 | Neovac Ltd. | Nanoparticle formulations for treatment of inflammations |
| WO2026021698A1 (en) | 2024-07-23 | 2026-01-29 | BioNTech SE | Nucleic acid particle |
| WO2026047603A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
| WO2026047148A1 (en) | 2024-08-29 | 2026-03-05 | BioNTech SE | Minimal polypeptide-encoding rnas |
| WO2026057625A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having a chap domain with engineered active site |
| WO2026057626A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having multiple enzymatically active domains |
| WO2026068864A1 (en) | 2024-09-30 | 2026-04-02 | BioNTech SE | Engineered ch1 and cl domains for the prevention of chain mispairing |
| WO2026082899A2 (en) | 2024-10-16 | 2026-04-23 | BioNTech SE | Rna for preventing or treating tuberculosis |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL58413C (https=) * | 1941-12-04 | |||
| US3703554A (en) * | 1969-07-22 | 1972-11-21 | Scm Corp | Terpenylamino ethers and thioethers |
| GB1367089A (en) * | 1970-07-23 | 1974-09-18 | Marumo H | Surface modifier for synthetic high polymers |
| US4034040A (en) * | 1971-05-24 | 1977-07-05 | Pfizer Inc. | Xylene-diamines as antiviral agents |
| JP3544429B2 (ja) * | 1996-04-25 | 2004-07-21 | 三菱製紙株式会社 | 可逆性感熱記録材料 |
| US20100047897A1 (en) | 2005-04-21 | 2010-02-25 | Santosh K Verma | Process for producing modified reconstituted sendai viral envelope specific for drug and/or gene delivery to liver cells |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| AU2010315124B2 (en) | 2009-11-04 | 2016-12-01 | Marina Biotech, Inc. | Activity generating delivery molecules |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| TW201408625A (zh) * | 2012-07-06 | 2014-03-01 | Kyowa Hakko Kirin Co Ltd | 陽離子性脂質 |
| HUE060907T2 (hu) * | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| WO2016021673A1 (ja) | 2014-08-06 | 2016-02-11 | 協和発酵キリン株式会社 | ｓｍａｌｌ ＲＮＡ含有医薬組成物の薬効を予測する方法 |
| AU2016253972B2 (en) | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
-
2017
- 2017-11-07 AU AU2017356699A patent/AU2017356699B2/en active Active
- 2017-11-07 US US16/347,995 patent/US11851389B2/en active Active
- 2017-11-07 CN CN201780082052.XA patent/CN110167922B/zh active Active
- 2017-11-07 DK DK17869620.9T patent/DK3538515T3/da active
- 2017-11-07 MX MX2019005287A patent/MX2019005287A/es unknown
- 2017-11-07 EP EP17869620.9A patent/EP3538515B1/en active Active
- 2017-11-07 ES ES17869620T patent/ES2928358T3/es active Active
- 2017-11-07 WO PCT/IL2017/051212 patent/WO2018087753A1/en not_active Ceased
- 2017-11-07 JP JP2019522244A patent/JP7075669B2/ja active Active
- 2017-11-07 PT PT178696209T patent/PT3538515T/pt unknown
-
2023
- 2023-10-18 US US18/489,240 patent/US20240246898A1/en active Pending
-
2024
- 2024-10-21 US US18/921,310 patent/US20250162978A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512272A5 (https=) | ||
| JP6018644B2 (ja) | １−［２−（２，４−ジメチル−フェニルスルファニル）−フェニル］−ピペラジンの製造方法 | |
| ES2567047T3 (es) | Derivados de pirimidina anti-virales | |
| ES2396267T3 (es) | Procedimiento para sintetizar compuestos útiles para el tratamiento de la hepatitis C | |
| ES2654364T3 (es) | Derivados de dolastatina 10 y auristatinas | |
| JP2010516635A5 (https=) | ||
| JP2011219498A5 (https=) | ||
| ES2496592T3 (es) | Proceso para la preparación de Imatinib y compuestos intermedios del mismo | |
| WO1996018608A1 (en) | Aniline derivatives having nitrogen monoxide synthase inhibitory activity | |
| CZ5797A3 (en) | Heterocyclic tachykinin receptor antagonists | |
| JP6832946B2 (ja) | キナーゼ阻害剤およびその中間体の調製方法 | |
| RU2014145819A (ru) | Бициклическое соединение | |
| TW200635585A (en) | Monocyclic substituted methanones | |
| CZ20024191A3 (cs) | Vodný roztok meloxicamu | |
| JPWO2014157612A1 (ja) | （１ｓ，４ｓ，５ｓ）−４−ブロモ−６−オキサビシクロ［３．２．１］オクタン−７−オンの製造方法 | |
| JP2009528318A5 (https=) | ||
| RU2017130474A (ru) | Замещенные триаозлы и способы, касающиеся их | |
| JP2017519796A5 (https=) | ||
| RU2008105304A (ru) | Соединение бензоимидазола, способное к ингибированию простагландин-d-синтетазы | |
| JP2021514399A5 (https=) | ||
| KR20180005214A (ko) | 질소 머스타드 유도체의 제조 방법 | |
| EP3628374B1 (en) | Bcl-3 inhibitors | |
| JP2020518621A5 (https=) | ||
| JP2022527213A5 (https=) | ||
| JP2005508382A5 (https=) |